TY - JOUR
T1 - Prognostic impact of phosphorylated HER-2 in HER-2 + primary breast cancer
AU - Hayashi, Naoki
AU - Iwamoto, Takayuki
AU - Gonzalez-Angulo, Ana M.
AU - Ferrer-Lozano, Jaime
AU - Lluch, Ana
AU - Niikura, Naoki
AU - Bartholomeusz, Chandra
AU - Nakamura, Seigo
AU - Hortobagyi, Gabriel N.
AU - Ueno, Naoto T.
PY - 2011/7
Y1 - 2011/7
N2 - Purpose. Tyrosine 1248 is one of the autophosphory-lation sites of human epidermal growth factor receptor (HER)-2. We determined the prognostic value of the expression level of tyrosine 1248-phosphorylated HER-2 (pHER-2) in patients with HER-2 + primary breast cancer using a reverse-phase protein array. Patients and Methods. The optimal cutoff value of pHER-2 for segregating disease-free survival (DFS) was determined by receiver operating characteristic (ROC) curve analysis. Five-year DFS for pHER-2 expression level was estimated with the Kaplan-Meier method using both derivation (n = 162) and validation (n = 227) cohorts. Results. Of the 162 patients in the derivation cohort, 26 had high HER-2 expression levels. The area under the ROC curve for pHER-2 level and DFS was 0.662. Nineteen of the 162 patients (11.7%) had high pHER-2 expression levels (pHER-2 high); 143 patients (88.3%) had low pHER-2 expression levels (pHER-2 low). Among the 26 patients with high HER-2 expression levels, the 17 pHER-2 high patients had a significantly lower 5-year DFS rate than the nine pHER-2 low patients (23.5% versus 77.8%). On multivariate analysis, only pHER-2 high independently predicted DFS in the Cox proportional hazards model. In the validation cohort, among 61 patients with high HER-2 expression, the difference in 5-year DFS rates between pHER-2 high (n = 7) and pHER-2 low (n = 54) patients was marginal (57.1% versus 81.5%).
AB - Purpose. Tyrosine 1248 is one of the autophosphory-lation sites of human epidermal growth factor receptor (HER)-2. We determined the prognostic value of the expression level of tyrosine 1248-phosphorylated HER-2 (pHER-2) in patients with HER-2 + primary breast cancer using a reverse-phase protein array. Patients and Methods. The optimal cutoff value of pHER-2 for segregating disease-free survival (DFS) was determined by receiver operating characteristic (ROC) curve analysis. Five-year DFS for pHER-2 expression level was estimated with the Kaplan-Meier method using both derivation (n = 162) and validation (n = 227) cohorts. Results. Of the 162 patients in the derivation cohort, 26 had high HER-2 expression levels. The area under the ROC curve for pHER-2 level and DFS was 0.662. Nineteen of the 162 patients (11.7%) had high pHER-2 expression levels (pHER-2 high); 143 patients (88.3%) had low pHER-2 expression levels (pHER-2 low). Among the 26 patients with high HER-2 expression levels, the 17 pHER-2 high patients had a significantly lower 5-year DFS rate than the nine pHER-2 low patients (23.5% versus 77.8%). On multivariate analysis, only pHER-2 high independently predicted DFS in the Cox proportional hazards model. In the validation cohort, among 61 patients with high HER-2 expression, the difference in 5-year DFS rates between pHER-2 high (n = 7) and pHER-2 low (n = 54) patients was marginal (57.1% versus 81.5%).
KW - Breast cancer
KW - HER-2
KW - Metastases
KW - Phosphorylation
KW - Reverse-phase protein array
UR - http://www.scopus.com/inward/record.url?scp=79960875009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960875009&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2010-0409
DO - 10.1634/theoncologist.2010-0409
M3 - Article
C2 - 21712485
AN - SCOPUS:79960875009
VL - 16
SP - 956
EP - 965
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 7
ER -